Literature DB >> 16604629

Design tools for proton therapy nozzles based on the double-scattering foil technique.

J D Fontenot1, W D Newhauser, U Titt.   

Abstract

Proton therapy has been increasing over the past several years, with several new treatment facilities being built in Europe, Japan and the United States. In this work, analytical and Monte Carlo tools were combined to model the passively scattered neurosurgery treatment beamline of the Harvard Cyclotron Laboratory (Cambridge, MA). The predicted three-dimensional dose distributions agree with actual measurements to within 0.1 mm for all quantities considered in central-axis depth-dose curve and to within 2.1 mm for all quantities considered in the absorbed dose cross-field profile. The predicted neutron dose equivalent per therapeutic absorbed dose, H/D, was calculated at various locations representing clinically significant anatomical sites. Under typical treatment conditions, the average ratio of predicted-to-measured H/D is 1.8 in the gonadal region (50 cm from isocentre) and 3.4 in the thyroid region (21 cm from isocentre). The global ratio of predicted-to-measured H/D is 2.6.

Mesh:

Substances:

Year:  2005        PMID: 16604629     DOI: 10.1093/rpd/nci229

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  21 in total

1.  Contribution to Neutron Fluence and Neutron Absorbed Dose from Double Scattering Proton Therapy System Components.

Authors:  A Pérez-Andújar; W D Newhauser; P M Deluca
Journal:  Nucl Technol       Date:  2009-01-01

2.  Monte Carlo and analytical model predictions of leakage neutron exposures from passively scattered proton therapy.

Authors:  Angélica Pérez-Andújar; Rui Zhang; Wayne Newhauser
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

3.  Microdosimetric measurements for neutron-absorbed dose determination during proton therapy.

Authors:  Angélica Pérez-Andújar; Paul M Deluca; Allan F Thornton; Markus Fitzek; Draik Hecksel; Jonathan Farr
Journal:  Radiat Prot Dosimetry       Date:  2012-02-14       Impact factor: 0.972

4.  Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams.

Authors:  Wayne D Newhauser; Laura Rechner; Dragan Mirkovic; Pablo Yepes; Nicholas C Koch; Uwe Titt; Jonas D Fontenot; Rui Zhang
Journal:  Radiat Meas       Date:  2013-11-01       Impact factor: 1.898

5.  ANALYTICAL MODEL TO ESTIMATE EQUIVALENT DOSE FROM INTERNAL NEUTRONS IN PROTON THERAPY OF CHILDREN WITH INTRACRANIAL TUMORS.

Authors:  Kyle J Gallagher; Phillip J Taddei
Journal:  Radiat Prot Dosimetry       Date:  2019-06-01       Impact factor: 0.972

6.  Maximum proton kinetic energy and patient-generated neutron fluence considerations in proton beam arc delivery radiation therapy.

Authors:  E Sengbusch; A Pérez-Andújar; P M DeLuca; T R Mackie
Journal:  Med Phys       Date:  2009-02       Impact factor: 4.071

7.  Neutron production from beam-modifying devices in a modern double scattering proton therapy beam delivery system.

Authors:  Angélica Pérez-Andújar; Wayne D Newhauser; Paul M Deluca
Journal:  Phys Med Biol       Date:  2009-01-16       Impact factor: 3.609

8.  Reduction of the secondary neutron dose in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator.

Authors:  David J Brenner; Carl D Elliston; Eric J Hall; Harald Paganetti
Journal:  Phys Med Biol       Date:  2009-09-24       Impact factor: 3.609

9.  Assessment of the accuracy of an MCNPX-based Monte Carlo simulation model for predicting three-dimensional absorbed dose distributions.

Authors:  U Titt; N Sahoo; X Ding; Y Zheng; W D Newhauser; X R Zhu; J C Polf; M T Gillin; R Mohan
Journal:  Phys Med Biol       Date:  2008-07-31       Impact factor: 3.609

10.  Monte Carlo simulation of the neutron spectral fluence and dose equivalent for use in shielding a proton therapy vault.

Authors:  Yuanshui Zheng; Wayne Newhauser; Eric Klein; Daniel Low
Journal:  Phys Med Biol       Date:  2009-11-04       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.